These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 483262)

  • 21. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism.
    Marder VJ; Donahoe JF; Bell WR; Cranley JJ; Kwaan HC; Sashara AA; Barlow GH
    J Lab Clin Med; 1978 Nov; 92(5):721-9. PubMed ID: 712206
    [No Abstract]   [Full Text] [Related]  

  • 22. [Thrombolytic action of urokinase preparation covalently bound to modified thrombin].
    Maksimenko AV; Tishvhenko EG; Petrov AD; Orekhova NM; Ragimov SE
    Biull Eksp Biol Med; 1988 Sep; 106(9):322-4. PubMed ID: 3167185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiation of the activation of Glu-plasminogen by streptokinase and urokinase in the presence of fibrinogen degradation products.
    Takada A; Takada Y
    Thromb Res; 1982 Feb; 25(3):229-35. PubMed ID: 7038978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Urokinase. Biochemical therapeutical and therapeutical data (author's transl)].
    Kher A
    Pathol Biol (Paris); 1976 Dec; 24 Suppl():54-69. PubMed ID: 64958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of thrombolytic treatment on natural inhibitors of coagulation-fibrinolysis, with report of pulmonary embolic cases.
    Hasegawa H; Nagata H; Murakoshi T; Yamauchi M; Oguma Y; Kamishima K; Murao M
    Nihon Ketsueki Gakkai Zasshi; 1979 Feb; 42(1):79-83. PubMed ID: 425795
    [No Abstract]   [Full Text] [Related]  

  • 27. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
    Thorsen S
    Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism.
    Griguer P; Charbonnier B; Latour F; Fauchier JP; Brochier M
    Angiology; 1979 Jan; 30(1):1-12. PubMed ID: 426316
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of fibrinogen and fibrin on the activation of Glu- and Lys-plasminogen by urokinase.
    Takada A; Takada Y; Sugawara Y
    Thromb Res; 1984 Mar; 33(6):561-9. PubMed ID: 6539003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of oral urokinase and its clinical application.
    Abe T; Kazama M; Naito I; Kinoshita T; Sasaki K
    New Istanbul Contrib Clin Sci; 1982; 13(3):161-70. PubMed ID: 6760114
    [No Abstract]   [Full Text] [Related]  

  • 32. [Indications for the use of thrombolytics in cases of cerebrovascular thrombosis also treated with hyperbaric oxygenation (2 ATA)].
    Larcan A; Laprevote-Heully MC; Lambert H; Alexandre P; Picard L; Chrisment N
    Therapie; 1977; 32(3):259-70. PubMed ID: 929497
    [No Abstract]   [Full Text] [Related]  

  • 33. Assay of urokinase activity in plasma with a chromogenic substrate.
    Hayashi S; Yamada K
    Thromb Res; 1981 Jun 1-25; 22(5-6):573-8. PubMed ID: 6171046
    [No Abstract]   [Full Text] [Related]  

  • 34. The enhanced activation of Glu-plasminogen by urokinase in the presence of fibrin or des A fibrin as measured by the release of B beta peptide and FDP.
    Urano T; Takada Y; Takada A
    Thromb Res; 1984 Dec; 36(5):429-35. PubMed ID: 6084324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of defibrinating agents ancrod and reptilase in the treatment of thromboembolism.
    Kwaan HC
    Thromb Diath Haemorrh Suppl; 1973; 56():239-51. PubMed ID: 4617331
    [No Abstract]   [Full Text] [Related]  

  • 36. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of different urokinase preparations.
    Millar WT; Smith JF
    Thromb Res; 1983 Jun; 30(5):425-9. PubMed ID: 6351343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen.
    Miles LA; Greengard JS; Griffin JH
    Thromb Res; 1983 Feb; 29(4):407-17. PubMed ID: 6344314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical and histochemical investigations on in vivo thrombolysis with urokinase in rabbits.
    Hisano S; Sueishi K; Ishii Y; Tanaka K
    Thromb Haemost; 1979 Jun; 41(4):796-803. PubMed ID: 483251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of plasminogen activation and hydrolysis of purified fibrinogen and fibrin by dextran 70.
    Carlin G; Bang NU
    Thromb Res; 1980 Aug 15-Sep 1; 19(4-5):535-46. PubMed ID: 6160642
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.